NCT01539993

Brief Summary

This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

February 15, 2012

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 28, 2012

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
Last Updated

May 28, 2014

Status Verified

May 1, 2014

Enrollment Period

5.2 years

First QC Date

February 15, 2012

Last Update Submit

May 23, 2014

Conditions

Liver Cancer

Keywords

Hepatocellular carcinomaLiver metastasesCholangiocarcinomaPercutaneous treatmentsRFATACEDEB

Outcome Measures

Primary Outcomes (1)

  • Assess efficacy of percutaneous and transarterial treatments for liver cancer.

    QOL questionnaire will be collected during follow up visit.

    1 month

Secondary Outcomes (1)

  • long term follow up

    3 months, 6 months 1year

Study Arms (1)

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for percutaneous liver treatments

You may qualify if:

  • Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

You may not qualify if:

  • Severe liver disfunction
  • Active uncontrolled infection
  • Significant underlying medical of physical illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emory University

Atlanta, Georgia, 30322, United States

Location

MeSH Terms

Conditions

Liver NeoplasmsCarcinoma, HepatocellularCholangiocarcinoma

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Kevin S Kim, MD

    Emory University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD FSIR, Director of Interventional Radiology and Image-Guided Medicine.

Study Record Dates

First Submitted

February 15, 2012

First Posted

February 28, 2012

Study Start

November 1, 2008

Primary Completion

January 1, 2014

Study Completion

January 1, 2014

Last Updated

May 28, 2014

Record last verified: 2014-05

Locations

US(1)